| Literature DB >> 30940906 |
Antonin Papin1,2,3, Benoit Tessoulin1,3,4, Céline Bellanger1,2,3, Anne Moreau3,5, Yannick Le Bris1,3,6, Hervé Maisonneuve3,7, Philippe Moreau1,3,4, Cyrille Touzeau1,3,4, Martine Amiot1,2,3, Catherine Pellat-Deceunynck1,2,3, Steven Le Gouill1,3,4, David Chiron8,9,10.
Abstract
The microenvironment strongly influences mantle cell lymphoma (MCL) survival, proliferation, and chemoresistance. However, little is known regarding the molecular characterization of lymphoma niches. Here, we focused on the interplay between MCL cells and the associated monocytes/macrophages. Using circulating MCL cells (n = 58), we showed that, through the secretion of CSF1 and, to a lesser extent, IL-10, MCL polarized monocytes into specific CD163+ M2-like macrophages (MϕMCL). In turn, MϕMCL favored lymphoma survival and proliferation ex vivo. We next demonstrated that BTK inhibition abrogated CSF1 and IL-10 production in MCL cells, leading to the inhibition of macrophage polarization and consequently resulting in the suppression of microenvironment-dependent MCL expansion. In vivo, we showed that CSF1 and IL-10 plasma concentrations were higher in MCL patients than in healthy donors, and that monocytes from MCL patients overexpressed CD163. Further analyses of serial samples from ibrutinib-treated patients (n = 8) highlighted a rapid decrease of CSF1, IL-10, and CD163 in responsive patients. Finally, we showed that targeting the CSF1R abrogated MϕMCL-dependent MCL survival, irrespective of their sensitivity to ibrutinib. These data reinforced the role of the microenvironment in lymphoma and suggested that macrophages are a potential target for developing novel therapeutic strategies in MCL.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30940906 DOI: 10.1038/s41375-019-0463-3
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528